The economic and humanistic burden of tenosynovial giant cell tumor: a targeted literature review

To understand the epidemiology, treatment patterns, economic burden, and humanistic burden of tenosynovial giant cell tumor (TGCT) in the contemporary treatment landscape. Embase, MEDLINE, and select conferences were searched to identify studies published between 1 January 2013, and 22/23 August 2023 (database dependent) that included ≥ 20 TGCT patients (≥ 40 for humanistic burden studies). For economic outcomes and treatment patterns, data from 1 January 2008, and later were included. A total of 35 studies were included. The incidence of TGCT was TGCT has a high burden, which can be exacerbated by repeat surgeries. Systemic therapies may improve disease and quality of life outcomes in some patients with tumors that are locally advanced or in complicated anatomical locations. Tenosynovial giant cell tumor (TGCT) is a rare disease that affects the joints and surrounding tissues. We reviewed published studies to understand how common TGCT is, current treatments, healthcare-related services and costs, and its impact on patients. Studies confirmed that TGCT is rare and that it impacts a relatively young population. Patients with TGCT commonly experience pain and stiffness and have less mobility and worse overall quality of life compared with the general population. Most patients with symptoms are treated with surgery. However, TGCT can come back after surgery in up to 2 out of 3 patients, potentially requiring them to undergo additional surgeries, which may be expensive and worsen symptoms. Alternatively, medications can be used for treatment and improve symptoms and quality of life for many patients. However, medications are not currently widely available and some are associated with negative side effects. More studies on existing medications and new medications that have fewer side effects are needed. In addition to surgery and medications, many patients receive physical therapy. Treatment decisions should consider the risks and benefits of all options on an individual basis.